Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Roberto Pili

Oncology
General Physician PC
45 Spindrift Dr, Suite 100, 
Williamsville, NY 

Advanced in WT1-Related Wilms Tumor Syndromes
General Physician PC
45 Spindrift Dr, Suite 100, 
Williamsville, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roberto Pili is an Oncologist in Williamsville, New York. Dr. Pili is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Bladder Cancer, Urothelial Cancer, and Orchiectomy.

His clinical research consists of co-authoring 157 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Kaleida Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

GENERAL PHYSICIAN PC
45 Spindrift Dr, Suite 100, Williamsville, NY 14221
Call: 716-422-5422

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase I/II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
A Phase I/II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: March 20, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab, Entinostat
Study Phase: Phase 1/Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Vorinostat
Study Phase: Phase 1
A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination With Nivolumab Plus Ipilimumab in Patients With Renal Cell Carcinoma Previously Treated With Nivolumab Plus Ipilimumab
A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination With Nivolumab Plus Ipilimumab in Patients With Renal Cell Carcinoma Previously Treated With Nivolumab Plus Ipilimumab
Enrollment Status: Terminated
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Gemcitabine, Atezolizumab, Docetaxel
Study Phase: Phase 2
A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Advanced Renal Cell Carcinoma
A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Advanced Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2023
Intervention Type: Drug
Study Drugs: Entinostat, Interleukin-2
Study Phase: Phase 2
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Enrollment Status: Active_not_recruiting
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drugs: Olaparib, Abiraterone acetate, Prednisone
Study Phase: Phase 2
A Pilot Feasibility Study of Sipuleucel-T vs. Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC)
A Pilot Feasibility Study of Sipuleucel-T vs. Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Completed
Publish Date: March 29, 2021
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

157 Total Publications

Elevated Likelihood of Infectious Complications Related to Oral Mucositis After Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis of Outcomes and Risk Factors.
Elevated Likelihood of Infectious Complications Related to Oral Mucositis After Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis of Outcomes and Risk Factors.
Journal: Cancers
Published: June 30, 2025
View All 157 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Saby R. George
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Saby R. George
Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (8.2 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Saby George is an Oncologist in Buffalo, New York. Dr. George is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Gurkamal S. Chatta
Oncology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Gurkamal S. Chatta
Oncology | Hematology Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (8.2 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gurkamal Chatta is an Oncologist and a Hematologist Oncology provider in Buffalo, New York. Dr. Chatta is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Bladder Cancer, Urothelial Cancer, Prostatectomy, and Orchiectomy.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Igor Puzanov
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Igor Puzanov
Hematology | Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (8.2 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Igor Puzanov is a Hematologist and an Oncologist in Buffalo, New York. Dr. Puzanov is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Breast Cancer, Tissue Biopsy, and Nephrectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pili's expertise for a condition
ConditionClose
  • Elite
  • Renal Cell Carcinoma (RCC)
    Dr. Pili is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Bladder Cancer
    Dr. Pili is
    Distinguished
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Prostate Cancer
    Dr. Pili is
    Distinguished
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Urothelial Cancer
    Dr. Pili is
    Distinguished
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
  • Advanced
  • Agranulocytosis
    Dr. Pili is
    Advanced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Pili is
    Advanced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Pili is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Prostate Cancer
    Dr. Pili is
    Advanced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Familial Wilms Tumor 2
    Dr. Pili is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Muscle Invasive Bladder Cancer
    Dr. Pili is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
View All 10 Advanced Conditions
  • Experienced
  • Adrenal Cancer
    Dr. Pili is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adult Soft Tissue Sarcoma
    Dr. Pili is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Pili is
    Experienced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Choriocarcinoma
    Dr. Pili is
    Experienced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Hereditary Neuroblastoma
    Dr. Pili is
    Experienced
    . Learn about Hereditary Neuroblastoma.
    See more Hereditary Neuroblastoma experts
  • Lung Cancer
    Dr. Pili is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved